Safety and efficacy of fimasartan in Mexican patients with grade 1–2 essential hypertension

Statistics

Clinical Research

Seguridad y eficacia de fimasartán en pacientes mexicanos con hipertensión esencial de grados 1–2

Ernesto G. Cardona-Muñoza,d, Agustín López-Alvaradob, Ignacio Conde-Carmonac,

Corresponding author

Ignacio.conde@stendhalpharma.com

Corresponding author at: Av. Camino a Santa Teresa No. 1040, Mezanine 1, Colonia Jardines en la Montaña, Delegación Tlalpan, C.P.: 14210, Ciudad de México, Mexico.

, Gerardo Sánchez-Mejoradac, Sara Pascoe-Gonzálezd, Ramiro G. Banda-Elizondoe, Armando García-Castillof, Guillermo González-Gálvezg, Raúl G. Velasco-Sánchezh, Maricela Vidrio-Velázquezi, José L. Leiva-Ponsj, Efraín Villeda-Espinosak, Arturo Guerra-Lópezl, Ramón M. Esturau-Santalom

a Investigación Clínica Especializada, Sociedad Civil, Guadalajara, Jalisco, Mexico

b Núcleo Médico La Paz, Guadalajara, Jalisco, Mexico

c Específicos Stendhal, S.A. de C.V., Ciudad de México, Mexico

d Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

e Centro de Estudios Clínicos y Especialidades Médicas, Monterrey, Nuevo León, Mexico

f Cardiolink Clinical Trials, Monterrey, Nuevo León, Mexico

g Instituto Jalisciense de Investigación en Diabetes y Obesidad S.C., Guadalajara, Jalisco, Mexico

h Hospital Dr. Ángel Leaño, Zapopan, Jalisco, Mexico

i Consultorio Médico Privado, Colonia Americana, Guadalajara, Jalisco, Mexico

j Hospital Central “Dr. Ignacio Morones Prieto”, San Luis Potosí, San Luis Potosí, Mexico

k Hospital de Jesús IAP, Ciudad de México, Mexico

l Centro Médico Excel, Tijuana, Baja California, Mexico

m Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara, Jalisco, Mexico

Read

11656

Times
was read the article

1783

Total PDF

9873

Total HTML

Share statistics

Article information

ISSN: 14059940
Original language: English

DOI:10.1016/j.acmx.2017.01.001

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 April	78	6	84
2024 March	185	22	207
2024 February	171	17	188
2024 January	181	13	194
2023 December	294	34	328
2023 November	269	13	282
2023 October	232	11	243
2023 September	334	6	340
2023 August	326	17	343
2023 July	397	16	413
2023 June	264	24	288
2023 May	324	19	343
2023 April	204	12	216
2023 March	327	17	344
2023 February	144	10	154
2023 January	108	6	114
2022 December	115	16	131
2022 November	130	43	173
2022 October	104	29	133
2022 September	177	41	218
2022 August	197	38	235
2022 July	142	35	177
2022 June	128	81	209
2022 May	146	44	190
2022 April	151	51	202
2022 March	229	40	269
2022 February	228	10	238
2022 January	220	30	250
2021 December	164	33	197
2021 November	136	21	157
2021 October	137	30	167
2021 September	94	26	120
2021 August	119	15	134
2021 July	94	31	125
2021 June	75	19	94
2021 May	71	11	82
2021 April	210	101	311
2021 March	274	38	312
2021 February	113	23	136
2021 January	109	30	139
2020 December	95	29	124
2020 November	105	15	120
2020 October	63	4	67
2020 September	74	14	88
2020 August	111	17	128
2020 July	94	21	115
2020 June	58	17	75
2020 May	88	7	95
2020 April	78	14	92
2020 March	106	11	117
2020 February	99	13	112
2020 January	91	13	104
2019 December	73	8	81
2019 November	61	7	68
2019 October	71	17	88
2019 September	78	11	89
2019 August	40	11	51
2019 July	53	14	67
2019 June	104	12	116
2019 May	221	57	278
2019 April	106	42	148
2019 March	25	9	34
2019 February	24	8	32
2019 January	28	12	40
2018 December	12	8	20
2018 November	25	4	29
2018 October	66	20	86
2018 September	47	9	56
2018 August	21	11	32
2018 July	30	9	39
2018 June	15	11	26
2018 May	25	16	41
2018 April	21	9	30
2018 March	28	7	35
2018 February	25	14	39
2018 January	37	9	46
2017 December	44	17	61
2017 November	35	17	52
2017 October	17	15	32
2017 September	6	10	16
2017 August	10	21	31
2017 July	8	2	10
2017 June	9	10	19
2017 May	16	21	37
2017 April	13	12	25
2017 March	16	42	58
2017 February	0	27	27

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter